Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Takout coming

<< Previous

Bullboard Posts

Next >>

Comment by PinnacleXon Dec 07, 2022 7:40pm

116 Views

Post# 35157824

RE:Takout coming

Trogarzon wrote: This debacle will bring a takout eventually... because the market is simply ignoring the entreprise value atm by a multiple of 3 at least... sick.

Company has 2 legacy drugs, nothing of value here left.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing